cytomyx set for a sept soar? (200+product launch)

Defence of placing price is a possible scenario.It might well be expected to move a tad higher.This is a well thought out deal the company has reinvented itself away from pure research aspirations to acknowledging revenue opportunities exist within the sector and taking advantage of them. The long term opportunities for this stock are good. Sound management has propelled them toward profitability. This time next year we should be looking at a very interesting proposition. DYOR....very sound, asset and product backed!